Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The MOAB Trial
NCT06069726Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Mar 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in glioblastoma (GBM), sponsored by Duke University. Primary endpoints: Overall Survival at 24 months and Overall Survival compared to historical control at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06069726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069726.